Severity of Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 Diminished during Successive Waves of the COVID-19 Pandemic: Data from a Nationwide German Survey
Epidemiology of 7375 children and adolescents hospitalized with COVID‑19 in Germany, reported via a prospective, nationwide surveillance study in 2020–2022 (Jan. 2024)
High burden of acute respiratory tract infections leading to hospitalization at German pediatric hospitals: fall/winter 2022-2023 (Nov. 2023)
A comparison of pediatric inflammatory multisystem syndrome temporarily-associated with SARS-CoV-2 and Kawasaki disease (Jan. 2023)
Aktualisierten S3-Leitlinie „Maßnahmen zur Prävention und Kontrolle der SARS-CoV-2-Übertragung in Schulen“ (Stand 30.09.2022)
SARS-CoV-2 variants and the risk of pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 among children in Germany (Sept. 2022)
SARS-CoV-2 variants and the risk of pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 among children in Germany (Sept. 2022)
Risk for severe outcomes of COVID-19 and PIMS-TS in children with SARS-CoV-2 infection in Germany (Aug. 2022)
Stellungnahme der DGPI, API, DGKJ, DGPK, GPOH, GKJR, GPP und STAKOB zur Klinik, Diagnostik und Therapie von Kindern mit COVID-19 (Stand 14.02.2022)
SARS-CoV-2 Prä-Expositionsprophylaxe (PrEP) mit neutralisierenden monoklonalen Antikörpern (Stand 25.11.2021)
Hinweise zur Impfung gegen SARS-CoV-2 (Covid-Impfung) bei kinderonkologischen Patienten (Stand 15.11.2021)
Prävention von Infektionen durch das Influenza- und respiratorische Synzytialvirus nach Aufhebung der Lockdown-Maßnahmen (Stand 17.08.2021)
